MedPath

Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial

Phase 3
Completed
Conditions
Chronic Migraine
Interventions
Device: Cefaly tDCS
Registration Number
NCT02122237
Lead Sponsor
University of Liege
Brief Summary

Cathodal tDCS decreases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in chronic migraine.

Detailed Description

During the interictal phase, the cerebral cortex is characterised by a hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical responses. Lack of habituation has been shown in the visual cortex in studies of visual evoked potentials (VEP) during the interictal period and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. Just before and during the migraine attack, cortical reactivity changes drastically: habituation is restored and the amplitude increases. In chronic migraine (headache occurring on 15 or more days per month for more than 3 months with features of migraine headache on at least 8 days per month), VEPs habituate normally like those recorded during attacks of episodic migraine, but have in addition an increased amplitude in the 1st block of responses. Chronic migraine was therefore compared to a "never ending migraine attack" accompanied by cortical hypersensitivity.

In this study the investigators aim to demonstrate that cathodal tDCS over the visual cortex with simultaneous anodal tDCS over the left dorsolateral prefrontal cortex is able: 1) to reduce cortical hypersensitivity and habituation as assessed by VEPs and contact heat evoked nociceptive potentials (CHEPS), as well as to decrease pain perception assessed by quantitative sensory testing (QST) and the nociceptive blink reflex (nBR); 2) to decrease headache and migraine frequency.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse
Exclusion Criteria
  • others diseases or contraindications to tDCS (epilepsy, pacemaker, metal prosthetics)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cathodal Cefaly tDCSCefaly tDCSCathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
Primary Outcome Measures
NameTimeMethod
Migraine frequency6 months

The investigators evaluate migraine frequency at baseline, during the treatment and 2 months after its end.

Secondary Outcome Measures
NameTimeMethod
Migraine intensity6 months

The investigators evaluate migraine intensity at baseline, during the treatment and 2 months after its end.

Attack duration6 months

The investigators evaluate attack duration at baseline, during the treatment and 2 months after its end.

Scores at psychological scales6 months

The investigators evaluate scores at psychological scales at baseline, during the treatment and 2 months after its end.

Acute medication intake6 months

The investigators evaluate acute medication intake at baseline, during the treatment and 2 months after its end.

Trial Locations

Locations (1)

Roberta Baschi

🇧🇪

Liège, Belgium

© Copyright 2025. All Rights Reserved by MedPath